Glaxo promises "sustainable" malaria vax price

Glaxo's Andrew Witty says he'll price the company's new malaria vaccine just over cost. And any profits, he pledges, will be plowed back into research. Analysts say that more than $500 million has been spent advancing the new vaccine through the pipeline. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.